IVD China last week: Canhelp Genomics & Eurobio Scientific, Agilent & Oebiotech, Wondfo, Maccura & Wellgrow Technology

Canhelp Genomics Partners with Eurobio Scientific to Expand European Markets

Canhelp Genomics announced the signing of a strategic partnership agreement with Eurobio Scientific, a leading European in vitro diagnostics (IVD) group listed on Euronext Paris. Under the agreement, Eurobio Scientific will serve as Canhelp Genomics’ commercial partner across major European Union and UK markets, promoting the company’s flagship products, Canhelp-Origin and Canhelp-UCa.

The collaboration will cover France, Germany, the United Kingdom, Austria, Switzerland, Belgium, the Netherlands, Luxembourg, and other key markets, while further strengthening the companies’ existing partnership in Italy. The agreement represents a significant milestone in Canhelp Genomics’ global expansion strategy and marks a new phase in the commercialization of its molecular diagnostic solutions in Europe.

Canhelp-Origin, a CE-IVD certified molecular diagnostic assay, is designed for tissue-of-origin identification in metastatic cancers. By analyzing a 90-gene expression signature, the test assists clinicians in determining the primary tumor site when conventional pathology and imaging methods are inconclusive, enabling more informed treatment decisions.Canhelp-UCa, also CE-IVD certified, is a non-invasive molecular diagnostic assay used for the auxiliary diagnosis and recurrence monitoring of urothelial carcinoma.

Agilent and Oebiotech Establish Strategic Partnership to Advance Quality Standards in Multi-Omics Services

Agilent Technologies and Shanghai Oebiotech Co., Ltd. have signed a strategic cooperation agreement. As part of the partnership, Oebiotech has been designated as an “Agilent Certified Laboratory for Excellence in Quality Control.”

Under the agreement, Oebiotech will adopt Agilent’s industry-leading sample quality control solutions across critical workflows, including sample testing, library quality control, and data analysis. The two companies aim to deliver high-quality, one-stop scientific research services to China’s life sciences community.

Oebiotech specializes in multi-omics research services, offering solutions in single-cell and spatial multi-omics, genomics, transcriptomics, epigenomics, proteomics, metabolomics, bioinformatics, and clinical diagnostic products.

Agilent stated that sample quality is a key determinant of experimental success. Leveraging its extensive technical expertise and proven quality control experience, the company will support Oebiotech in strengthening its quality management system and enhancing the consistency and reliability of its omics services.

WONDFO and the Third Affiliated Hospital of Guangzhou Medical University Launch Preeclampsia Screening and Prevention Initiative

WONDFO and the Third Affiliated Hospital of Guangzhou Medical University recently signed an agreement to jointly establish a Hypertensive Disorders of Pregnancy and Preeclampsia Screening and Prevention Center.

The partnership aims to strengthen maternal and infant healthcare through the development of comprehensive screening and prevention programs for preeclampsia, supporting the implementation of China’s Healthy China strategy.Combining the hospital’s extensive clinical expertise in obstetrics with WONDFO’s advanced diagnostic technologies and product portfolio, the two parties will develop precise, accessible, and efficient screening and lifecycle management solutions for pregnant women.

Beyond clinical applications, the collaboration will expand into joint research projects, national key initiatives, technology commercialization, and ecosystem development. WONDFO has established a dedicated project team covering product planning, IT infrastructure, medical research, and market development to ensure effective implementation and data quality management, with the goal of bringing innovative diagnostic solutions to more families.

Maccura and Wellgrow Technology Join Forces to Build Smart Laboratory Ecosystem

Maccura Biotechnology and Shenzhen Wellgrow Technology officially signed a Strategic Cooperation Agreement on Intelligent Laboratory Ecosystem Integration. The partnership will combine the core technological strengths of both companies to jointly develop an intelligent laboratory ecosystem. Wellgrow Technology becomes the first analytical systems manufacturer to join Maccura’s smart laboratory ecosystem initiative.

For Maccura, the collaboration strengthens its laboratory automation and intelligence platform by expanding capabilities in analytical systems and flow cytometry solutions. For Wellgrow Technology, the partnership provides access to Maccura’s nationwide distribution network, accelerating the clinical adoption of its products.

Together, the two companies aim to advance the development of intelligent diagnostic laboratory solutions, improving efficiency and expanding access to precision diagnostics for healthcare institutions and patients.